Shares of Hims & Hers Health Inc ( HIMS ) are trading higher Wednesday morning, fueled by a wave of investor confidence following an insider stock purchase by a key member of the company’s leadership team. Here’s what investors need to know.

Hims & Hers Health ( HIMS ) stock is among today’s top performers. What’s fueling HIMS momentum?

Board Member David Wells Drops Seven Figures On The Dip

According to fresh SEC Form 4 regulatory filings, David Wells, a member of the Hims & Hers Board of Directors and the former Chief Financial Officer of Netflix, executed a massive open-market purchase of the company’s Class A common stock.

Wells snapped up 48,400 shares at a weighted average price of $24.23 per share, representing a total out-of-pocket investment of more than $1.17 million. This transaction significantly expands his long-term conviction in the telehealth firm, increasing his direct ownership stake by roughly 27.5% to a total of 224,417 shares.

HIMS Stock: Key Levels And Momentum Indicators

Today's strength is happening while the stock is still trying to repair longer-term damage: it's down 52.45% over the past 12 months and remains 26.9% below its 200-day SMA ($34.80), which keeps the bigger trend biased lower. At the same time, shares are holding above the 50-day SMA ($24.23) and 100-day SMA ($24.22), and the 20-day SMA is above the 50-day SMA—an early "rebuild" signal that often shows up before a more durable trend change.

RSI is the cleaner momentum read right now, sitting at 45.59, which points to neutral-to-soft momentum rather than an overbought chase. In plain terms, RSI helps gauge whether buying or selling has gotten stretched; here it suggests the bounce is still tentative, not overheated.

Key Resistance: $30.50 — a nearby round-number area that lines up with where rebounds can stall before the longer-term trend fully improves

Key Support: $21.50 — a nearby prior demand zone that becomes more important if the post-financing volatility returns

What Is Hims & Hers Health’s Business Model?

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers across areas like erectile dysfunction, hair loss, skin care, mental health, and weight loss. It sells a mix of generic, branded and compounded prescription drugs plus over-the-counter products, cosmetics and supplements.

The platform has more than 2 million subscribers and operates in all 50 states plus certain European markets like the UK, supported by provider networks, electronic medical records, cloud pharmacy fulfillment and personalization tools.

Because it doesn't take insurance and relies on direct customer payments, funding decisions and expansion plans (including the proposed Eucalyptus acquisition expected to close in mid-2026) can have an outsized impact on how investors handicap growth versus dilution.

HIMS Stock Price Movement On Wednesday

HIMS Stock Price Activity: Hims & Hers Health ( HIMS ) shares were up 6.37% at $25.37 at the time of publication on Wednesday, according to Benzinga Pro data.

Image: Shutterstock